Tremfya

Guselkumab

Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. As monotherapy or in combination w/ methotrexate for active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

SC 100 mg at wk 0 & 4, followed by maintenance dose every 8 wk. Consider 100 mg every 4 wk for patients w/ psoriatic arthritis at high risk for joint damage according to clinical judgement.

Serious hypersensitivity. Clinically important active infections (eg, active TB).

Discontinue use in case of serious hypersensitivity reactions. Avoid psoriatic skin as inj sites. Increased risk of infection. Do not initiate in patients w/ any clinically important active infection until it resolves or is adequately treated. Evaluate for TB prior to treatment initiation. Monitor for signs & symptoms of active TB during & after treatment. Evaluate liver enzymes at baseline & thereafter when prescribing Tremfya every 4 wk in psoriatic arthritis. Temporarily interrupt treatment if increases in ALT or AST are observed & drug-induced liver injury is suspected. Live vaccines should not be used concurrently. W/hold treatment for at least 12 wk after last dose prior to live viral or bacterial vaccination; treatment can be resumed 2 wk after vaccination. Patients w/ renal or hepatic impairment. Women of childbearing potential should use effective methods of contraception during & for at least 12 wk after treatment. Preferable to avoid use during pregnancy. Lactation. Elderly ≥65 yr. Childn & adolescents <18 yr.

Resp tract infections. Increased transaminases; headache; diarrhoea; arthralgia; inj site reactions.

Safety & efficacy in combination w/ immunosuppressants (eg, biologics) or phototherapy have not been evaluated.

Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations

L04AC16 - guselkumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

P₁S₁S₃